Improving access to affordable quality-assured inhaled medicines in low- and middle-income countries.

Marie Stolbrink; Martha Chinouya; S. Jayasooriya; Becky Nightingale; L. Evans-Hill; K. Allan; H. Allen; J. Balen; T. Beacon; K. Bissell; J. Chakaya; C. Y. Chiang; M. Cohen; Graham Devereux; A. El Sony; D. M.G. Halpin; J. R. Hurst; C. Kiprop; A. Lawson; C. Macé; A. Makhanu; P. Makokha; R. Masekela; H. Meme; E. M. Khoo; Rebecca Nantanda; S. Pasternak; C. Perrin; H. Reddel; S. Rylance; P. Schweikert; C. Were; S. Williams; T. Winders; A. Yorgancioglu; G. B. Marks; Kevin Mortimer

doi:10.5588/ijtld.22.0270

Improving access to affordable quality-assured inhaled medicines in low- and middle-income countries.

Marie Stolbrink, Martha Chinouya, S. Jayasooriya, Becky Nightingale, L. Evans-Hill, K. Allan, H. Allen, J. Balen, T. Beacon, K. Bissell, J. Chakaya, C. Y. Chiang, M. Cohen, Graham Devereux, A. El Sony, D. M.G. Halpin, J. R. Hurst, C. Kiprop, A. Lawson, C. MacéA. Makhanu, P. Makokha, R. Masekela, H. Meme, E. M. Khoo, Rebecca Nantanda, S. Pasternak, C. Perrin, H. Reddel, S. Rylance, P. Schweikert, C. Were, S. Williams, T. Winders, A. Yorgancioglu, G. B. Marks, Kevin Mortimer

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)

Abstract

BACKGROUND: Access to affordable inhaled medicines for chronic respiratory diseases (CRDs) is severely limited in low- and middle-income countries (LMICs), causing avoidable morbidity and mortality. The International Union Against Tuberculosis and Lung Disease convened a stakeholder meeting on this topic in February 2022.

METHODS: Focused group discussions were informed by literature and presentations summarising experiences of obtaining inhaled medicines in LMICs. The virtual meeting was moderated using a topic guide around barriers and solutions to improve access. The thematic framework approach was used for analysis.

RESULTS: A total of 58 key stakeholders, including patients, healthcare practitioners, members of national and international organisations, industry and WHO representatives attended the meeting. There were 20 pre-meeting material submissions. The main barriers identified were 1) low awareness of CRDs; 2) limited data on CRD burden and treatments in LMICs; 3) ineffective procurement and distribution networks; and 4) poor communication of the needs of people with CRDs. Solutions discussed were 1) generation of data to inform policy and practice; 2) capacity building; 3) improved procurement mechanisms; 4) strengthened advocacy practices; and 5) a World Health Assembly Resolution.

CONCLUSION: There are opportunities to achieve improved access to affordable, quality-assured inhaled medicines in LMICs through coordinated, multi-stakeholder, collaborative efforts.

Original language	English
Pages (from-to)	1023-1032
Number of pages	10
Journal	International Journal of Tuberculosis and Lung Disease
Volume	26
Issue number	11
DOIs	https://doi.org/10.5588/ijtld.22.0270
Publication status	Published - 1 Nov 2022

Keywords

asthma
chronic respiratory disease
COPD
essential medicines
inhalers
non-communicable disease

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.5588/ijtld.22.0270Licence: CC BY

PMC9621306Final published version, 1.36 MBLicence: CC BY

Cite this

Stolbrink, M., Chinouya, M., Jayasooriya, S., Nightingale, B., Evans-Hill, L., Allan, K., Allen, H., Balen, J., Beacon, T., Bissell, K., Chakaya, J., Chiang, C. Y., Cohen, M., Devereux, G., El Sony, A., Halpin, D. M. G., Hurst, J. R., Kiprop, C., Lawson, A., ... Mortimer, K. (2022). Improving access to affordable quality-assured inhaled medicines in low- and middle-income countries. International Journal of Tuberculosis and Lung Disease, 26(11), 1023-1032. https://doi.org/10.5588/ijtld.22.0270

@article{d7386dde2d06461e9a6fd28432c55c3a,

title = "Improving access to affordable quality-assured inhaled medicines in low- and middle-income countries.",

abstract = "BACKGROUND: Access to affordable inhaled medicines for chronic respiratory diseases (CRDs) is severely limited in low- and middle-income countries (LMICs), causing avoidable morbidity and mortality. The International Union Against Tuberculosis and Lung Disease convened a stakeholder meeting on this topic in February 2022.METHODS: Focused group discussions were informed by literature and presentations summarising experiences of obtaining inhaled medicines in LMICs. The virtual meeting was moderated using a topic guide around barriers and solutions to improve access. The thematic framework approach was used for analysis.RESULTS: A total of 58 key stakeholders, including patients, healthcare practitioners, members of national and international organisations, industry and WHO representatives attended the meeting. There were 20 pre-meeting material submissions. The main barriers identified were 1) low awareness of CRDs; 2) limited data on CRD burden and treatments in LMICs; 3) ineffective procurement and distribution networks; and 4) poor communication of the needs of people with CRDs. Solutions discussed were 1) generation of data to inform policy and practice; 2) capacity building; 3) improved procurement mechanisms; 4) strengthened advocacy practices; and 5) a World Health Assembly Resolution.CONCLUSION: There are opportunities to achieve improved access to affordable, quality-assured inhaled medicines in LMICs through coordinated, multi-stakeholder, collaborative efforts.",

keywords = "asthma, chronic respiratory disease, COPD, essential medicines, inhalers, non-communicable disease",

author = "Marie Stolbrink and Martha Chinouya and S. Jayasooriya and Becky Nightingale and L. Evans-Hill and K. Allan and H. Allen and J. Balen and T. Beacon and K. Bissell and J. Chakaya and Chiang, \{C. Y.\} and M. Cohen and Graham Devereux and \{El Sony\}, A. and Halpin, \{D. M.G.\} and Hurst, \{J. R.\} and C. Kiprop and A. Lawson and C. Mac{\'e} and A. Makhanu and P. Makokha and R. Masekela and H. Meme and Khoo, \{E. M.\} and Rebecca Nantanda and S. Pasternak and C. Perrin and H. Reddel and S. Rylance and P. Schweikert and C. Were and S. Williams and T. Winders and A. Yorgancioglu and Marks, \{G. B.\} and Kevin Mortimer",

year = "2022",

month = nov,

day = "1",

doi = "10.5588/ijtld.22.0270",

language = "English",

volume = "26",

pages = "1023--1032",

journal = "International Journal of Tuberculosis and Lung Disease",

issn = "1027-3719",

publisher = "International Union Against Tuberculosis and Lung Disease ",

number = "11",

}

Stolbrink, M, Chinouya, M, Jayasooriya, S, Nightingale, B, Evans-Hill, L, Allan, K, Allen, H, Balen, J, Beacon, T, Bissell, K, Chakaya, J, Chiang, CY, Cohen, M, Devereux, G, El Sony, A, Halpin, DMG, Hurst, JR, Kiprop, C, Lawson, A, Macé, C, Makhanu, A, Makokha, P, Masekela, R, Meme, H, Khoo, EM, Nantanda, R, Pasternak, S, Perrin, C, Reddel, H, Rylance, S, Schweikert, P, Were, C, Williams, S, Winders, T, Yorgancioglu, A, Marks, GB & Mortimer, K 2022, 'Improving access to affordable quality-assured inhaled medicines in low- and middle-income countries.', International Journal of Tuberculosis and Lung Disease, vol. 26, no. 11, pp. 1023-1032. https://doi.org/10.5588/ijtld.22.0270

TY - JOUR

T1 - Improving access to affordable quality-assured inhaled medicines in low- and middle-income countries.

AU - Stolbrink, Marie

AU - Chinouya, Martha

AU - Jayasooriya, S.

AU - Nightingale, Becky

AU - Evans-Hill, L.

AU - Allan, K.

AU - Allen, H.

AU - Balen, J.

AU - Beacon, T.

AU - Bissell, K.

AU - Chakaya, J.

AU - Chiang, C. Y.

AU - Cohen, M.

AU - Devereux, Graham

AU - El Sony, A.

AU - Halpin, D. M.G.

AU - Hurst, J. R.

AU - Kiprop, C.

AU - Lawson, A.

AU - Macé, C.

AU - Makhanu, A.

AU - Makokha, P.

AU - Masekela, R.

AU - Meme, H.

AU - Khoo, E. M.

AU - Nantanda, Rebecca

AU - Pasternak, S.

AU - Perrin, C.

AU - Reddel, H.

AU - Rylance, S.

AU - Schweikert, P.

AU - Were, C.

AU - Williams, S.

AU - Winders, T.

AU - Yorgancioglu, A.

AU - Marks, G. B.

AU - Mortimer, Kevin

PY - 2022/11/1

Y1 - 2022/11/1

N2 - BACKGROUND: Access to affordable inhaled medicines for chronic respiratory diseases (CRDs) is severely limited in low- and middle-income countries (LMICs), causing avoidable morbidity and mortality. The International Union Against Tuberculosis and Lung Disease convened a stakeholder meeting on this topic in February 2022.METHODS: Focused group discussions were informed by literature and presentations summarising experiences of obtaining inhaled medicines in LMICs. The virtual meeting was moderated using a topic guide around barriers and solutions to improve access. The thematic framework approach was used for analysis.RESULTS: A total of 58 key stakeholders, including patients, healthcare practitioners, members of national and international organisations, industry and WHO representatives attended the meeting. There were 20 pre-meeting material submissions. The main barriers identified were 1) low awareness of CRDs; 2) limited data on CRD burden and treatments in LMICs; 3) ineffective procurement and distribution networks; and 4) poor communication of the needs of people with CRDs. Solutions discussed were 1) generation of data to inform policy and practice; 2) capacity building; 3) improved procurement mechanisms; 4) strengthened advocacy practices; and 5) a World Health Assembly Resolution.CONCLUSION: There are opportunities to achieve improved access to affordable, quality-assured inhaled medicines in LMICs through coordinated, multi-stakeholder, collaborative efforts.

AB - BACKGROUND: Access to affordable inhaled medicines for chronic respiratory diseases (CRDs) is severely limited in low- and middle-income countries (LMICs), causing avoidable morbidity and mortality. The International Union Against Tuberculosis and Lung Disease convened a stakeholder meeting on this topic in February 2022.METHODS: Focused group discussions were informed by literature and presentations summarising experiences of obtaining inhaled medicines in LMICs. The virtual meeting was moderated using a topic guide around barriers and solutions to improve access. The thematic framework approach was used for analysis.RESULTS: A total of 58 key stakeholders, including patients, healthcare practitioners, members of national and international organisations, industry and WHO representatives attended the meeting. There were 20 pre-meeting material submissions. The main barriers identified were 1) low awareness of CRDs; 2) limited data on CRD burden and treatments in LMICs; 3) ineffective procurement and distribution networks; and 4) poor communication of the needs of people with CRDs. Solutions discussed were 1) generation of data to inform policy and practice; 2) capacity building; 3) improved procurement mechanisms; 4) strengthened advocacy practices; and 5) a World Health Assembly Resolution.CONCLUSION: There are opportunities to achieve improved access to affordable, quality-assured inhaled medicines in LMICs through coordinated, multi-stakeholder, collaborative efforts.

KW - asthma

KW - chronic respiratory disease

KW - COPD

KW - essential medicines

KW - inhalers

KW - non-communicable disease

U2 - 10.5588/ijtld.22.0270

DO - 10.5588/ijtld.22.0270

M3 - Article

SN - 1027-3719

VL - 26

SP - 1023

EP - 1032

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

IS - 11

ER -

Improving access to affordable quality-assured inhaled medicines in low- and middle-income countries.

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this